Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection

Expert Opinion on Investigational Drugs

Volumn 21, Issue 6, 2012, Pages 773-783

  MacKiewicz, Andrzej ^a,b,c   MacKiewicz, Jacek ^b   Wysocki, Piotr J ^a   Wiznerowicz, MacIej ^a,d   Kapcinska, Malgorzata ^a,b   Laciak, Maria ^a,c   Rose John, Stefan ^a,c   Izycki, Dariusz ^e,f   Burzykowski, Tomasz ^a   Karczewska Dzionk, Aldona ^g  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b GREATER POLAND CANCER CENTRE   (Poland)

^c BioContract Sp Z Oo   (Poland)

^d GREATER POLAND CANCER CENTER   (Poland)

^e UNIVERSITY OF KIEL   (Germany)

^f Kiel and Lungen Clinic Grosshansdorf   (Germany)

^g HASSELT UNIVERSITY   (Belgium)

Author keywords

Advanced melanoma; Genetic melanoma vaccine; Long term survivals; Phase II clinical trials; Re induction

Indexed keywords

AGI 101; AGI 101H; MELANOMA VACCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE EDEMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EDEMA; FEMALE; FEVER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNIZATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYALGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRURITUS; SIDE EFFECT; SKIN REDNESS; SWEATING;

ADULT; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84861052254     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.684753     Document Type: Article

References (46)

1. Garbe C, Eigrntler ThK, Keilholz U, et al. Systemic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5-24
2. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-18
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with Vemurafenib. N Engl J Med 2012;366:707-14
4. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9 (Pubitemid 44547756)
5. Hodi FS, O'Day S, McDermont DF, et al. Improved survival with ipilumumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
6. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology group Trial EST 1684. J Clin Oncol 1996;14:7-17 (Pubitemid 26019991)
7. Davar D, Tarhini A, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J 2012;18:192-202
8. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
9. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
10. Feun LG, Guttermann J, Burgess MA, et al. The natural history of resectable metastatic melanoma. Cancer 1982;50:1656-63 (Pubitemid 12034567)
11. Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J 2012;18:176-84
12. Eggermont AMM, Testori A, Maio M, et al. Anti-CTL-4 antibody adjuvant therapy in Melanoma. Semin Oncol 2010;37:455-9
13. Mackiewicz J, Mackiewicz A. Immunotargeting of melanoma. In: Cao MY, editor. Current Management of Malignant Melanoma. InTech; Rijeka: 2011. p. 93-118.Available from: www. intechopen.com
14. Piantadosi S. Clinical Trials: A Methodologic Perspective. 2nd edition. Wiley; Hoboken, NJ: 2005. Sec. 11.4.7
15. Mackiewicz A. Vaccine compositions. EP 2, 252-322 (2009);
16. Mackiewicz A, Wysocki PJ, Suchorska W. Vaccine compositions. US2011002898; 2010.Available from: www. freepatentsonline.com/y2011/0002898. html .
17. Fisher M, Goldschmitt J, Peschel C, et al. A bioactive designer cytokine for human hematopoetic cell expansion. Nat Biotechnol 1997;15:142-5 (Pubitemid 27081778)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16 (Pubitemid 30099779)
19. Collet D. Modelling Survival Data in Medical Research. 2nd edition. Chapman&Hall/CRC; Boca Raton: 2003
20. Parmiani G, Pilla L, Maccalli C, Russo V. Autologous versus allogeneic cell-based vaccines ? Cancer J 2011;17:331-6
21. Mackiewicz J, Mackiewicz A. Gene-modified cellular vaccines: technologic aspects and clinical problems. Transpl Proc 2010;42:3287-92
22. Morton DL, Mozzilo N, Thomson JF, et al. An international, randomized, phase III trial of baccilus Calmette-Geurin (BCG) plus allogeneic cell vaccine (MCV) or placebo after complete resection of melanoma metsetases to regional or distant sites. J Clin Oncol 2007;25(18 Suppl):abstract 8508
23. Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M, Mackiewicz A. Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther 2004;4:1595-607 (Pubitemid 39371755)
24. Arienti F, Belli F, Napolitano F, et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1999;10:2907-16
25. Osanto S, Schiphorst PP, Weijl NI, et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther 2000;11:739-50 (Pubitemid 30180278)
26. Belli F, Arienti F, Sule-Suso J, et al. Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 1997;44:197-203 (Pubitemid 27288127)
27. Maio M, Fonsatti E, Lamaj E, et al. Vaccination of stage IV patients with allogeneic IL-4-or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2002;52:9-14 (Pubitemid 34158518)
28. Nawrocki S, Murawa P, Malicki J, et al. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 2000;74:81-6
29. Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34 . (Pubitemid 351264344)
30. Mitchel MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007;25:2078-85 (Pubitemid 46972794)
31. Hersey P, Caotes AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma. Results of randomized trail. J Clin Oncol 2002;20:4181-90 (Pubitemid 35191020)
32. Eggermont AMM, Suciu S, Samtinam M, et al. Adjuvant therapy with pegylated interferon alpha-2b versus observation in resected stage III melanoma. Final results of EORTC 18891, a randomized phase 3 trial. Lancet 2008;372:117-26 (Pubitemid 351952257)
33. Eigentler TK, Radny P, Hauschild A, et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008;18:363-8
34. Bystryn J-C, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882-7 (Pubitemid 32994821)
35. Coventry BJ, Hersey P, Halligan A-M, et al. Immuno-chemotherapy using repeated vaccine treatment can produce successful clinical responses in advanced metastatic melanoma. J Cancer Ther 2010;1:295-13
36. Hoos A, Parmiani G, Hege K. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15 (Pubitemid 46052199)
37. Nawrocki S, Mackiewicz A. Clinical trials of active cancer immunotherapy. Expert Opin Investig Drugs 2007;16:1137-41 .
38. Mackiewicz J, Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur J Pharmacol 2009;625:84-9
39. Eggermont MM. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009;15:6745-7
40. Atanackovic D, Altorki NK, Cao Y, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. PNAS 2008;105:1650-5 (Pubitemid 351346569)
41. Mackiewicz A, Schooltink H, Heinrich P, Rose-John S. Soluble human IL-6-receptor/IL-6 up-regulates expression of acute phase proteins. J Immunol 1992;149:2021-7 .
42. Mackiewicz A, Wiznerowicz M, Roeb E, et al. Soluble interleukin-6 receptor is biologically active in vivo. Cytokine 1995;7:142-9
43. Izycki D, Nawrocki S, Filas V, et al. IL-6 and soluble IL-6 receptor gene modified tumor vaccine induces more efficient anti-melanoma immune responses and polarizes response towards Th1 type. Pol J Environ Stud 2005;14:139-59
44. Mackiewicz A, Gorny A, Laciak M, et al. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 1995;6:805-11 .
45. Wysocki PJ, Kazimierczak U, Suchorska W, et al. Gene-modified tumor vaccine secreting Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gen Ther 2010;17:465-75 .
46. Wolchok JD, Hoos A, O'Day S. Guidelines for evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20